MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
15.25
0.00
0.00%
After Hours: 15.25 0 0.00% 16:10 02/11 EST
OPEN
15.27
PREV CLOSE
15.25
HIGH
15.51
LOW
14.64
VOLUME
2.68M
TURNOVER
--
52 WEEK HIGH
36.91
52 WEEK LOW
13.83
MARKET CAP
11.35B
P/E (TTM)
-12.2806
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SMMT last week (0202-0206)?
Weekly Report · 2d ago
Avacta Group Appoints Francis Wilson as Chief Scientific Officer
Reuters · 2d ago
Pfizer: Messy Q4 Earnings Mask An Improving Business
Seeking Alpha · 02/03 19:02
Summit Therapeutics: Ivonescimab’s De-Risked Regulatory Path and Multi-Indication Upside Support $40 Target and Buy Rating
TipRanks · 02/02 11:46
Summit Therapeutics Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 02/02 11:36
HC Wainwright & Co. Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
Benzinga · 02/02 11:26
Weekly Report: what happened at SMMT last week (0126-0130)?
Weekly Report · 02/02 09:21
Summit Therapeutics Grants Stock Options to New Employees
Reuters · 01/30 21:30
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.